AI Analysis | Feedback

• Like a European and African counterpart to North American medical cannabis producers such as Tilray (TLRY) or Canopy Growth (CGC).
• A burgeoning 'Pfizer (PFE) for medical cannabis' focused on the European market.

AI Analysis | Feedback

• Medical Cannabis Flower: Cultivation and supply of high-quality, GMP-certified dried cannabis flower for medicinal use.
• Medical Cannabis Extracts & Oils: Manufacturing and distribution of cannabis oils, tinctures, and other extract-based products for medical applications.
• Medical Cannabis Distribution Services: Importation, warehousing, and distribution of medical cannabis products to pharmacies and clinics across the UK and European markets.

AI Analysis | Feedback

• Cansativa Group: A leading medical cannabis distributor in Germany. Cansativa is a private company.
• RUA Medical (a subsidiary of RUA Life Sciences plc): A medical device company based in the UK with whom Akanda has a sales and distribution agreement for certain markets, including the UK. RUA Life Sciences plc is a public company traded on the London Stock Exchange under the symbol RUA.L.

AI Analysis | Feedback

null

AI Analysis | Feedback

Katharyn Field, Executive Director and Interim Chief Executive Officer

Ms. Field served as Executive Vice President of Corporate Development at MariMed in 2018. Prior to that, she ran a strategy consulting practice focused on the cannabis industry. She holds an MBA from Columbia Business School and a BA with honors from Stanford University. Ms. Field is also the President of Halo, which holds approximately 41% of Akanda's voting securities.

Gurcharn Deol, Chief Financial Officer

Mr. Deol is a multi-industry executive with over 35 years of public company management experience. His recent experience includes serving as a director or in management of numerous Canadian private and public companies, such as Bayridge Resources Inc., Trilogy AI Corp, and Green Battery Minerals Inc. He has been involved in initial public offerings (IPOs), guiding private companies through the regulatory process to go public.

Christopher Cooper, Director and President of First Towers

Mr. Cooper has over 20 years of extensive business experience across corporate development, senior management, finance, and operations in both private and public sectors. He has served as a director for several private and public companies over the past two decades.

AI Analysis | Feedback

1. High Probability of Financial Distress and Bankruptcy: Akanda Corp. has a very high probability of experiencing financial distress, with one analysis indicating an 88% chance of distress over the next two years. This figure is substantially higher than averages for both the biotechnology sector and the broader healthcare industry. The company's financial statements reflect decreasing total assets and declining cash reserves, contributing to this elevated risk.
2. Significant Operating Losses and Debt Burden: The company has reported substantial operating losses, with an operating income margin of -382.34% as of Q2 2023. Akanda is also navigating a significant debt burden, which could lead to difficulties in making interest payments. While the company has made efforts to reduce debt through asset sales, its overall financial health remains under scrutiny due to these ongoing losses.
3. High Stock Volatility and Negative Market Sentiment: Akanda's stock is characterized by high price volatility and, at times, low trading volume, classifying it as a "high risk" investment. The stock has experienced a dramatic decline in value over various periods, including an 88.98% fall over one year as of April 2024. Market analysts have generally issued a "Sell" rating for Akanda, reflecting negative investor sentiment and concerns about its future performance.

AI Analysis | Feedback

The clear emerging threat for Akanda is the rapid advancement and potential commercialization of synthetic and biosynthesized cannabinoids. Companies are developing methods to produce various cannabinoids (including rare ones) through precision fermentation and other lab-based processes, rather than traditional plant cultivation. If these methods become scalable, cost-effective, and widely accepted by regulators and consumers, they could significantly undermine the value proposition of cannabis cultivators like Akanda, which rely on agricultural production. This represents a fundamental technological shift in cannabinoid production that could lead to lower costs, greater consistency, and reduced reliance on geographical or agricultural factors, potentially disrupting the entire supply chain that Akanda currently operates within.

AI Analysis | Feedback

Akanda Corp. (AKAN) operates in the cannabis industry, focusing on medical cannabis products and wellness and lifestyle CBD-based products, alongside cultivation, supply chain, and distribution services. The company's primary market of interest, based on its headquarters and distribution focus, is Europe, particularly the United Kingdom.

Addressable Market Sizes:

Medical Cannabis Products

• Europe: The European medical cannabis market was valued at approximately USD 6.06 billion in 2024 and is projected to reach USD 36.2 billion by 2033, growing at a Compound Annual Growth Rate (CAGR) of 21.97% from 2024 to 2033. Another estimate placed the market size at USD 3.51 billion in 2024, expected to reach USD 35.59 billion by 2032, with a CAGR of 33.60% during the forecast period. A different source estimated the European medical cannabis market size in 2024 to be €779 million.
• United Kingdom: The UK Medical Cannabis Market was valued at USD 28.47 million in 2024 and is projected to grow to USD 37.52 million by 2032, at a CAGR of 3.27%.

CBD-Based Wellness and Lifestyle Products

• Europe: The Europe cannabidiol (CBD) market size was estimated at USD 347.7 million in 2023 and is expected to grow at a CAGR of 25.8% from 2024 to 2030. Another estimate for the European CBD market in 2024 is €1.97 billion.
• United Kingdom: The UK CBD market size reached USD 893.75 million in 2024 and is expected to reach USD 2,399.90 million by 2033, exhibiting a CAGR of 11.60% during 2025-2033. Another report valued the U.K. Cannabidiol Market at USD 1355.6 million in 2023, expecting it to reach USD 5066.7 million by 2030, with a CAGR of 24.58%. The UK CBD market is forecast to potentially surpass £1 billion in 2025.

AI Analysis | Feedback

Expected Drivers of Future Revenue Growth for Akanda (AKAN)

1. Expansion of Telecommunications Infrastructure in Mexico: Akanda, through its wholly-owned subsidiary First Towers & Fiber Corp. (FTF), plans to construct and/or acquire up to 20 new or existing cellular towers by the end of 2025. This initiative builds on FTF's existing portfolio of 30 operational revenue-generating towers and 700-kilometer dark fiber network in Mexico. This strategic investment is designed to strengthen coverage, increase network capacity, and generate long-term recurring revenue.
2. Securing Future 5G Expansion Contracts in Mexico: With FTF becoming a key player in expanding Mexico's LTE and 4G networks, Akanda aims to secure future contracts for 5G expansion. This is expected to enhance its operational position and financial standing through strategic investments and improved outsourcing options.
3. Increased Utilization and Partnerships in Mexican Telecom: Each additional tower in the FTF network is expected to drive incremental cash flow, enhance network utilization, and provide scalable infrastructure for existing partnerships. This will reinforce FTF's role as a preferred partner for Altan and CFE, positioning it to capture increasing demand for mobile data and enterprise connectivity solutions in Mexico.
4. Growth in Plant-Based Wellness Therapeutics (Cannabis Sector): Akanda Corp. continues its operations in the cannabis industry, focusing on the production and distribution of cannabis and cannabis-derived products. The company's ongoing involvement in the plant-based wellness therapeutics sector indicates an ongoing focus on generating revenue from this segment.

AI Analysis | Feedback

Share Issuance

• On April 26, 2023, Akanda issued 78,865 Common Shares for approximately $330,647 (JPY50,000,410).
• On September 25, 2023, Akanda issued 78,865 Common Shares for approximately $330,647 (JPY50,000,410).
• On October 31, 2023, Akanda issued an aggregate of 268,140 Common Shares to two investors for approximately $1,124,195 (JPY170,000,760).

Inbound Investments

• Akanda Corp. was acquired by First Towers & Fiber Corp. in a reverse merger transaction as of August 21, 2025.

Outbound Investments

• Akanda agreed to sell its subsidiary, Holigen, for a total consideration of approximately $35 million, which included $3,750,000 in cash and 1,900,000 common shares in Akanda (valued at $10.30 per share on April 19, 2022), plus the indirect assumption of RPK's indebtedness of approximately $5,100,000 and at least $834,000 of interim funding to Holigen.

Capital Expenditures

• Akanda's capital expenditures for the latest twelve months (as of the most recent data) were approximately -$754,245.
• Akanda's capital expenditures averaged $685,239 for fiscal years ending December 2020 to 2024.
• Capital expenditures for Akanda peaked in December 2024 at $2.098 million.

Share Repurchases

• Akanda does not appear to pay any dividends, and its buyback yield in the last 12 months was -607.47%.
• Akanda had reverse stock splits of 1-for-40 effective May 23, 2024, and 1-for-2 effective November 14, 2024, which reduced outstanding common shares.